Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review

Evidence has shown that women with a history of preeclampsia or haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome have an increased risk of cardiovascular disease later in life. Recommendations for screening, prevention and management after such pregnancies are not yet defined. T...

Full description

Saved in:
Bibliographic Details
Main Authors: Esmee ME Bovee, Martha Gulati, Angela HEM Maas
Format: Article
Language:English
Published: Radcliffe Medical Media 2021-09-01
Series:European Cardiology Review
Online Access:https://www.ecrjournal.com/articleindex/ecr.2021.21
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850256465485365248
author Esmee ME Bovee
Martha Gulati
Angela HEM Maas
author_facet Esmee ME Bovee
Martha Gulati
Angela HEM Maas
author_sort Esmee ME Bovee
collection DOAJ
description Evidence has shown that women with a history of preeclampsia or haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome have an increased risk of cardiovascular disease later in life. Recommendations for screening, prevention and management after such pregnancies are not yet defined. The identification of promising non-traditional cardiovascular biomarkers might be useful to predict which women are at greatest risk. Many studies are inconsistent and an overview of the most promising biomarkers is currently lacking. This narrative review provides an update of the current literature on circulating cardiovascular biomarkers that may be associated with an increased cardiovascular disease risk in women after previous preeclampsia/HELLP syndrome. Fifty-six studies on 53 biomarkers were included. From the summary of evidence, soluble fms-like tyrosine kinase-1, placental growth factor, interleukin (IL)-6, IL-6/IL-10 ratio, high-sensitivity cardiac troponin I, activin A, soluble human leukocyte antigen G, pregnancy-associated plasma protein A and norepinephrine show potential and are interesting candidate biomarkers to further explore. These biomarkers might be potentially eligible for cardiovascular risk stratification after preeclampsia/HELLP syndrome and may contribute to the development of adequate strategies for prevention of hypertension and adverse events in this population.
format Article
id doaj-art-c1f3a2bf47534202b416901e418169ec
institution OA Journals
issn 1758-3756
1758-3764
language English
publishDate 2021-09-01
publisher Radcliffe Medical Media
record_format Article
series European Cardiology Review
spelling doaj-art-c1f3a2bf47534202b416901e418169ec2025-08-20T01:56:38ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642021-09-011610.15420/ecr.2021.21Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative ReviewEsmee ME Bovee0Martha Gulati1Angela HEM Maas2Radboud University, Nijmegen, the NetherlandsUniversity of Arizona, Phoenix, Arizona, USDepartment of Cardiology, Radboud University Medical Center, Nijmegen, the NetherlandsEvidence has shown that women with a history of preeclampsia or haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome have an increased risk of cardiovascular disease later in life. Recommendations for screening, prevention and management after such pregnancies are not yet defined. The identification of promising non-traditional cardiovascular biomarkers might be useful to predict which women are at greatest risk. Many studies are inconsistent and an overview of the most promising biomarkers is currently lacking. This narrative review provides an update of the current literature on circulating cardiovascular biomarkers that may be associated with an increased cardiovascular disease risk in women after previous preeclampsia/HELLP syndrome. Fifty-six studies on 53 biomarkers were included. From the summary of evidence, soluble fms-like tyrosine kinase-1, placental growth factor, interleukin (IL)-6, IL-6/IL-10 ratio, high-sensitivity cardiac troponin I, activin A, soluble human leukocyte antigen G, pregnancy-associated plasma protein A and norepinephrine show potential and are interesting candidate biomarkers to further explore. These biomarkers might be potentially eligible for cardiovascular risk stratification after preeclampsia/HELLP syndrome and may contribute to the development of adequate strategies for prevention of hypertension and adverse events in this population.https://www.ecrjournal.com/articleindex/ecr.2021.21
spellingShingle Esmee ME Bovee
Martha Gulati
Angela HEM Maas
Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review
European Cardiology Review
title Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review
title_full Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review
title_fullStr Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review
title_full_unstemmed Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review
title_short Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review
title_sort novel cardiovascular biomarkers associated with increased cardiovascular risk in women with prior preeclampsia hellp syndrome a narrative review
url https://www.ecrjournal.com/articleindex/ecr.2021.21
work_keys_str_mv AT esmeemebovee novelcardiovascularbiomarkersassociatedwithincreasedcardiovascularriskinwomenwithpriorpreeclampsiahellpsyndromeanarrativereview
AT marthagulati novelcardiovascularbiomarkersassociatedwithincreasedcardiovascularriskinwomenwithpriorpreeclampsiahellpsyndromeanarrativereview
AT angelahemmaas novelcardiovascularbiomarkersassociatedwithincreasedcardiovascularriskinwomenwithpriorpreeclampsiahellpsyndromeanarrativereview